Repository logo
 
Publication

The role of benralizumab in eosinophilic immune dysfunctions: a case report-based literature review

dc.contributor.authorGomes, Margarida
dc.contributor.authorMendes, Ana
dc.contributor.authorFerreira, Filipa
dc.contributor.authorBranco, Joana
dc.contributor.authorTonin, Fernanda
dc.contributor.authorPedro, M. Elisa
dc.date.accessioned2023-05-17T11:42:40Z
dc.date.available2023-05-17T11:42:40Z
dc.date.issued2023-04
dc.description.abstractIn the past years, the knowledge of eosinophils playing a primary pathophysiologic role in several associated conditions has led to the development of biologics targeting therapies aiming at normalizing the immune response, reducing chronic inflammation, and preventing tissue damage. To better illustrate the potential relationship between different eosinophilic immune dysfunctions and the effects of biological therapies in this scenario, here, we present a case of a 63-year-old male first referred to our department in 2018 with a diagnosis of asthma, polyposis, and rhinosinusitis and presenting a suspicion of nonsteroidal anti-inflammatory drugs' allergy. He also had a past medical history of eosinophilic gastroenteritis/duodenitis (eosinophilia counts >50 cells/high-power field HPF). The use of multiple courses of corticosteroid therapy failed to completely control these conditions. In October 2019, after starting benralizumab (an antibody directed against the alpha chain of the IL-5 cytokine receptor) as an add-on treatment for severe eosinophilic asthma, important clinical improvements were reported both in the respiratory (no asthma exacerbations) and gastrointestinal systems (eosinophilia count 0 cells/HPF). The patient's quality of life also increased. Since June 2020, systemic corticosteroid therapy was reduced without worsening gastrointestinal symptoms or eosinophilic inflammation. This case warns of the importance of early recognition and appropriate individualized treatment of eosinophilic immune dysfunctions and suggests the conduction of further larger studies on the use of benralizumab in gastrointestinal syndromes aiming at better understanding its relying mechanisms of action in the intestinal mucosa.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationGomes M, Mendes A, Ferreira F, Branco J, Tonin FS, Pedro ME. The role of benralizumab in eosinophilic immune dysfunctions: a case report-based literature review. Case Rep Med. 2023;2023:8832242.pt_PT
dc.identifier.doi10.1155/2023/8832242pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.21/16055
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherHindawipt_PT
dc.relation.publisherversionhttps://www.hindawi.com/journals/crim/2023/8832242/pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/pt_PT
dc.subjectEosinophilic immune dysfunctionspt_PT
dc.subjectBenralizumabpt_PT
dc.subjectCase reportpt_PT
dc.subjectLiterature reviewpt_PT
dc.titleThe role of benralizumab in eosinophilic immune dysfunctions: a case report-based literature reviewpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.startPage8832242pt_PT
oaire.citation.titleCase Reports in Medicinept_PT
oaire.citation.volume2023pt_PT
person.familyNameTonin
person.givenNameFernanda
person.identifier.ciencia-idD01C-C700-9411
person.identifier.orcid0000-0003-4262-8608
person.identifier.ridO-2050-2017
person.identifier.scopus-author-id56085115800
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication61ded30e-ecec-4b3e-b953-2293e080ebdd
relation.isAuthorOfPublication.latestForDiscovery61ded30e-ecec-4b3e-b953-2293e080ebdd

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
The role of benralizumab in eosinophilic immune dysfunctions_a case report-based literature review.pdf
Size:
1.03 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:

Collections